Henan Cancer Hospital
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
The Maintenance Treatment of "ITIVA" in AML Patients
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT06256627
- Locations
- 🇨🇳
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06236997
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Tongji Hospital, Tongji Medical College，Huazhong University of Science and Technology, Wuhan, Hubei, China
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
- Conditions
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT06231680
- Locations
- 🇨🇳
Ying Liu, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT06227325
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
- Conditions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT06176534
- Locations
- 🇨🇳
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06160362
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Go-CHOP as the Frontline Therapy for PTCL
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05963347
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain
- Conditions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 916
- Registration Number
- NCT05962294
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT05923541
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 610
- Registration Number
- NCT05918328
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China